非经典menin靶点的表观遗传调控调节急性髓系白血病对menin抑制剂的反应
研究通过染色质聚焦CRISPR筛选及遗传、表观遗传和药理学研究,在多种人源和小鼠KMT2A重排急性髓系白血病模型中,发现由活性menin与抑制性H2AK119ub标记双价共占的非经典menin靶点在menin抑制后通常下调;PRC1.1亚基(如PCGF1或BCOR)缺失通过表观遗传再激活这些非经典靶点(包括MYC)导致menin抑制剂耐药,抑制MYC或联合维奈克拉可克服该耐药。
要点
- PRC1.1亚基PCGF1或BCOR缺失通过再激活非经典menin靶点(包括MYC)导致menin抑制剂耐药
- 遗传或药理抑制MYC可使PRC1.1缺陷白血病细胞对menin抑制重新敏感
- PRC1.1缺陷白血病细胞单核细胞基因特征降低、对BCL2抑制敏感,维奈克拉联合可克服耐药
核心结论
- PRC1.1及其调控的非经典menin靶点在调节menin抑制剂反应中起重要作用,并为治疗PRC1.1功能受损的白血病提供潜在策略。
研究设计与样本
- 通过系统性染色质聚焦CRISPR筛选,结合遗传、表观遗传和药理学研究,在多种人源和小鼠KMT2A重排急性髓系白血病模型中开展研究。
主要发现
- 一组被活性menin和抑制性H2AK119ub标记双价共占的非经典menin靶点,在menin抑制后通常下调。
- PRC1.1亚基PCGF1或BCOR缺失通过表观遗传再激活包括MYC在内的非经典靶点,导致menin抑制剂耐药。
- 遗传和药理抑制MYC可使PRC1.1缺陷白血病细胞对menin抑制重新敏感。
- PRC1.1亚基缺失的白血病细胞单核细胞基因特征降低,并对BCL2抑制敏感。
- 维奈克拉联合治疗可克服PRC1.1缺陷白血病细胞对menin抑制的耐药。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Menin inhibitors that disrupt the menin-MLL interaction hold promise for treating specific acute myeloid leukemia (AML) subtypes, including those with KMT2A rearrangements (KMT2A-r), yet resistance remains a challenge. Here, through systematic chromatin-focused CRISPR screens, along with genetic, epigenetic, and pharmacologic studies in a variety of human and mouse KMT2A-r AML models, we uncovered a potential resistance mechanism independent of canonical menin-MLL targets. We show that a group of noncanonical menin targets, which are bivalently cooccupied by active menin and repressive H2AK119ub marks, are typically downregulated after menin inhibition. Loss of polycomb repressive complex 1.1 (PRC1.1) subunits, such as polycomb group ring finger 1 (PCGF1) or BCL6 corepressor (BCOR), leads to menin inhibitor resistance by epigenetic reactivation of these noncanonical targets, including MYC. Genetic and pharmacological inhibition of MYC can resensitize PRC1.1-deficient leukemia cells to menin inhibition. Moreover, we demonstrate that leukemia cells with the loss of PRC1.1 subunits exhibit reduced monocytic gene signatures and are susceptible to BCL2 inhibition, and that combinational treatment with venetoclax overcomes the resistance to menin inhibition in PRC1.1-deficient leukemia cells. These findings highlight the important roles of PRC1.1 and its regulated noncanonical menin targets in modulating the menin inhibitor response and provide potential strategies to treat leukemia with compromised PRC1.1 function.
引用
- Zhou X, Zhang L, Aryal S, et al. Epigenetic regulation of noncanonical menin targets modulates menin inhibitor response in acute myeloid leukemia. Blood. 2024. PMID: 39158067. doi:10.1182/blood.2023023644
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。